UNSPSC 51183611: Liraglutide

This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 839I73S42A. European Medicines Agency schedules Liraglutide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25238. Liraglutide generally arises in the molecular formula C172H265N43O51.

The term LIRAGLUTIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 17, no. 2uy, 2003, list 49.) Most nations, for tariff and trade purposes, schedule liraglutide under HS 29371900 and SITC 54154. As of Q4 2014, LIRAGLUTIDE remains US FDA's Preferred Term for this commodity. Liraglutide bears US NLM identifiers UMLS ID C1456408 and NCI Concept Code C82239.

UNSPSC 51183611 Liraglutide, a Commodity code, covers the procurement of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist pharmaceutical used to treat type 2 diabetes and obesity. State and local governments—primarily public health departments, Medicaid agencies, correctional health systems, and public hospitals—purchase liraglutide as part of formulary coverage for eligible beneficiaries and inmates. The drug is dispensed through pharmacy benefit programs, health plan channels, and direct institutional procurement. Issuing bodies include state Medicaid agencies (which manage the largest volume of liraglutide acquisition for eligible recipients), county health systems, municipal public hospitals, state and local correctional facilities, and regional healthcare authorities.

The source provided contains no recent state and local contract opportunities posted under UNSPSC 51183611. Without posted RFPs, RFQs, IFBs, or ITBs naming liraglutide procurement, geographic concentration and near-term buying activity cannot be characterized from current market signals. State and local procurement of prescription pharmaceuticals often occurs through standing state purchasing cooperative agreements, Medicaid managed-care plan negotiations, or vendor-direct arrangements rather than through open competitive notices, which limits visibility into this code's active solicitation pipeline.